 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PAVmed and Lucid Diagnostics to Participate in Panel Presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference PAVmed and Lucid Diagnostics to Participate in Panel Presentation at the...

PAVmed and Lucid Diagnostics to Participate in Panel Presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Lucid Diagnostics management to meet virtually with Needham

Lucid Diagnostics Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard Esophageal Precancer Detection Lucid Diagnostics Releases Positive Data from First Prospective...

Lucid Diagnostics Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard Esophageal Precancer Detection

Lucid Diagnostics Executes First Direct Employer Contract to Provide EsoGuard Esophageal Precancer Testing as an Employee Benefit Lucid Diagnostics Executes First Direct Employer Contract to Provide...

Lucid Diagnostics Executes First Direct Employer Contract to Provide EsoGuard Esophageal Precancer Testing as an Employee Benefit

Lucid Diagnostics (NASDAQ:LUCD  Get Free Report)s stock had its overweight rating reissued by stock analysts at Cantor Fitzgerald in a report released on Tuesday, Benzinga...

Cantor Fitzgerald Reiterates "Overweight" Rating for Lucid Diagnostics (NASDAQ:LUCD)

Lucid Diagnostics Inc. (NASDAQ:LUCD Free Report) Equities research analysts at Cantor Fitzgerald boosted their FY2023 EPS estimates for Lucid Diagnostics in a report released on Thursday, August 17th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will earn ($1.14) per share ...

Analysts Set Expectations for Lucid Diagnostics Inc.'s FY2023 Earnings (NASDAQ:LUCD)

Lucid Diagnostics Inc. (NASDAQ:LUCD  Free Report)  Cantor Fitzgerald upped their FY2023 EPS estimates for shares of Lucid Diagnostics in a research note issued to investors on Thursday, August 17th. Cantor Fitzgerald analyst R. Osborn now expects that the company will post earnings per...

FY2023 EPS Estimates for Lucid Diagnostics Inc. Lifted by Cantor Fitzgerald (NASDAQ:LUCD)

Needham & Company LLC reaffirmed their buy rating on shares of Lucid Diagnostics (NASDAQ:LUCD Free Report) in a research note published on Wednesday morning, Benzinga reports. They currently have a $2.80 price objective on the stock. Separately, Cantor Fitzgerald decreased their price objective on ...

Needham & Company LLC Reaffirms "Buy" Rating for Lucid Diagnostics (NASDAQ:LUCD)

Lucid Diagnostics (NASDAQ:LUCD Get Free Report)s stock had its overweight rating reaffirmed by equities research analysts at Cantor Fitzgerald in a report released on Wednesday, Benzinga reports. They currently have a $4.00 price objective on the stock. Cantor Fitzgeralds target price suggests a ...

Lucid Diagnostics (NASDAQ:LUCD) Given Overweight Rating at Cantor Fitzgerald

PAVmed Provides Business Update and Second Quarter Financial Results PAVmed Provides Business Update and Second Quarter Financial Results PR Newswire NEW YORK, Aug. 15, 2023 EsoGuard test volume continues to grow as Lucid makes strides with commercial expansion and additional supporting data Veris...

PAVmed Provides Business Update and Second Quarter Financial Results

Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company was founded by Lishan Aklog on May 8, 2018 and is headquartered in New York, NY.

Watchers	1,242
52-Wk Low	$1.11
52-Wk High	$2.36

Market Cap	$61.52M
Volume (M)	45,454.00
52-Wk High	$2.36
52-Wk Low	$1.11

LUCD Lucid Diagnostics Inc

About

Feed

News

Earnings

Fundamentals